On November 12, 2024, Adial Pharmaceuticals, Inc. conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders approved an amendment to the company's 2017 Equity Incentive Plan, increasing the number of shares authorized for grant from 500,000 to 2,000,000. Additionally, two Class III directors were re-elected to serve a three-year term, and Marcum, LLP was ratified as the company's independent registered public accounting firm for the year ending December 31, 2024. The compensation of named executive officers was approved on an advisory basis, and a three-year frequency for future advisory votes on executive compensation was established. The Board of Directors has decided to adhere to this frequency for holding advisory votes on executive compensation.

On November 12, 2024, Adial Pharmaceuticals, Inc. conducted its 2024 Annual Meeting of Stockholders, where several key proposals were voted upon. The stockholders approved an amendment to the company's 2017 Equity Incentive Plan, increasing the number of shares authorized for grant from 500,000 to 2,000,000. Additionally, two Class III directors were re-elected to serve a three-year term, and Marcum, LLP was ratified as the company's independent registered public accounting firm for the year ending December 31, 2024. The compensation of named executive officers was approved on an advisory basis, and a three-year frequency for future advisory votes on executive compensation was established. The Board of Directors has decided to adhere to this frequency for holding advisory votes on executive compensation.